Clearside Biomedical, Inc. Announces Fifth Patent Issued in the U.S. Related To Proprietary Microneedle Drug Delivery Methods and Devices

ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye, today announced the U.S. Patent and Trademark Office (USPTO) granted U.S. Patent Application No. 14/523,243 as U.S. Patent No. 9,180,047 in a patent titled, "Apparatus and Methods for Ocular Injection."

U.S. Patent No. 9,180,047 relates to methods for ocular injection and expands Clearside’s intellectual property portfolio. Use of Clearside’s proprietary suprachoroidal space (SCS™) technology is disclosed in the patent. This is the fifth patent allowance in the United States related to its proprietary microneedle drug delivery methods and devices.

The SCS™ Microinjector is used in Clearside’s investigational clinical trials. Using CLS-TA, Clearside’s proprietary formulation of triamcinolone acetonide developed specifically for administration using the SCS™ Microinjector, Clearside has initiated the enrollment process in a Phase 3 clinical trial, Peachtree, which is a randomized, masked, controlled clinical trial to study the efficacy and safety of CLS-TA for the treatment of patients with macular edema associated with non-infectious uveitis. Clearside’s ongoing Phase 2 trial, Tanzanite, is assessing the efficacy and safety of CLS-TA used concomitantly with an intravitreal injection-delivered VEGF inhibitor in patients with macular edema associated with retinal vein occlusion. Clearside recently completed enrollment of the third trial, Dogwood, a Phase 2 trial evaluating the efficacy and safety of CLS-TA in patients with macular edema associated with non-infectious uveitis.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye. Clearside’s product candidates focus on diseases of the eye, especially diseases associated with macular edema. Clearside Biomedical holds intellectual property protecting the delivery of drugs of any type through the SCS™ to reach the delicate tissues of the choroid and retina. Visit www.clearsidebio.com for more information.